Market revenue in 2020 | USD 152.8 million |
Market revenue in 2028 | USD 485.7 million |
Growth rate | 15.6% (CAGR from 2020 to 2028) |
Largest segment | Lymphoma |
Fastest growing segment | Lymphoma |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Leukemia, Lymphoma, MPNs, Other Cancers |
Key market players worldwide | Roche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.
Lymphoma was the largest segment with a revenue share of 46.79% in 2020. Horizon Databook has segmented the Canada hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.
The hemato oncology testing market in Canada is expected to witness lucrative growth owing to increasing prevalence of blood cancer and growing awareness about early diagnosis & treatment. As per data published by Canadian Cancer Society, it was projected that in 2021 6,700 people will be diagnosed with leukemia and 3,100 will die from it in Canada.
Increasing regulatory approvals and launch of technologically advanced hemato oncology solutions in the region are expected to support the market growth over the forecast period.
For instance, in November 2018, MolecularMD, a U.S.-based hemato oncology solutions developer received Health Canada approval for MRDx BCR-ABL Test, intended for Treatment-free Remission (TFR) for patients with Philadelphia chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) treated with Tasigna.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into Canada hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account